Targeting fat-tissue hormone may lead to type 2 diabetes treatment

December 23, 2015, Harvard T.H. Chan School of Public Health
A fatty acid–binding protein called aP2 has been linked to obesity, diabetes, and heart disease in humans. New research in mice shows that an antibody therapy blocking aP2 can help reverse some of the metabolic disturbances associated with type 2 diabetes. Credit: V. Altounian / Science Translational Medicine

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases. The researchers developed an antibody that improves glucose regulation and reduces fatty liver in obese mice by targeting a hormone in adipose (fat) tissue called aP2 (also known as FABP4).

The study will be published online December 23, 2015 in Science Translational Medicine.

"The importance of this study is two-fold: first, demonstrating the importance of aP2 as a critical hormone in abnormal glucose metabolism, and secondly, showing that aP2 can be effectively targeted to treat diabetes and potentially other immunometabolic diseases," said Gökhan S. Hotamisligil, J.S. Simmons Professor of Genetics and Metabolism and chair of the Department of Genetics and Complex Diseases and the Sabri Ülker Center at Harvard Chan School.

The work is the product of a collaboration on immunometabolism between the biopharmaceutical company UCB and a team of researchers led by Hotamisligil and lead author M. Furkan Burak, a former Hotamisligil lab member and currently a resident in internal medicine at Mount Auburn Hospital, Cambridge, MA. This partnership successfully twins UCB's world-class expertise in monoclonal antibody discovery with Hotamisligil's insight and experience in aP2 biology.

The increase in adipose tissue characteristic of obesity has long been linked to increased risk for such as type 2 diabetes and cardiovascular disease. Recently, it has become clear that the tissue itself plays an active role in metabolic disease, in part by releasing hormones which act in distant sites such as the liver, muscle, and brain that affect systemic metabolism. Work from the Hotamisligil lab previously identified the protein aP2 as a critical hormone mediating communication between adipose tissue and liver. Since aP2 levels are significantly increased in humans with obesity, diabetes, and atherosclerosis, and mutations that reduce aP2 result in significantly reduced risk of diabetes, dyslipidemia, and heart disease, strategies to modify aP2 function carry promise as new lines of therapeutic entities against these common and debilitating chronic diseases.

In the new study, Burak and colleagues describe the development and evaluation of novel monoclonal antibodies targeting aP2. The team found that one of these antibodies effectively improved in two independent models of obesity. Additionally, beneficial reductions in liver fat were observed.

These monoclonal antibodies have the potential to be transformative first-in-class therapeutics to fight obesity-related metabolic and immunometabolic disease, say the authors. This work is still at the preclinical stage and will require extensive evaluation for safety and effectiveness before being considered for use in humans.

Explore further: Discovery of new hormone opens doors to new type 2 diabetes treatments

More information: "Development of a therapeutic monoclonal antibody that targets secreted fatty acid binding protein aP2 to treat type 2 diabetes," M. Furkan Burak, Karen E. Inouye, Ariel White, Alexandra Lee, Gurol Tuncman, Ediz S. Calay, Motohiro Sekiya, Amir Tirosh, Kosei Eguchi, Gabriel Birrane, Daniel Lightwood, Louise Howells, Geofrey Odede, Hanna Hailu, Shauna West, Rachel Garlish, Helen Neale, Carl Doyle, Adrian Moore, Gökhan S. Hotamisligil, Science Translational Medicine, online December 23, 2015. stm.sciencemag.org/lookup/doi/ … scitranslmed.aac6336

Related Stories

Discovery of new hormone opens doors to new type 2 diabetes treatments

May 7, 2013
Harvard School of Public Health (HSPH) researchers have discovered that a particular type of protein (hormone) found in fat cells helps regulate how glucose (blood sugar) is controlled and metabolized (used for energy) in ...

Newly identified molecular mechanism plays role in type 2 diabetes development

July 30, 2015
New research from Harvard T.H. Chan School of Public Health describes a molecular mechanism that helps explain how obesity-related inflammation can lead to type 2 diabetes. The findings describe a surprising connection between ...

New tool identifies novel compound targeting causes of type 2 diabetes

June 17, 2015
A new drug screening technology developed at the Harvard T.H. Chan School of Public Health has identified a new potential anti-diabetes compound—and a powerful way to quickly test whether other molecules can have a positive ...

Excessive contact between cellular organelles disrupts metabolism in obesity

November 24, 2014
Researchers at Harvard School of Public Health (HSPH) have found a novel mechanism causing type 2 diabetes that could be targeted to prevent or treat the disease. The research highlights a previously unrecognized molecular ...

Sex reassignment surgery may be better for transgender women's health than hormones only

November 19, 2015
Emerging evidence suggests that transgender women have a higher risk of developing cardiovascular disease and type 2 diabetes compared with men and women in the general population. A preliminary study to be presented at Cardiovascular, ...

Lipid enzyme heightens insulin sensitivity, potential therapy to treat Type 2 diabetes

July 16, 2015
Reducing high concentrations of a fatty molecule that is commonly found in people with diabetes and nonalcoholic fatty liver disease rapidly improves insulin sensitivity, UT Southwestern Medical Center diabetes researchers ...

Recommended for you

Women with pregnancy-related diabetes may be at risk for chronic kidney disease

May 21, 2018
Gestational diabetes may predispose women to early-stage kidney damage, a precursor to chronic kidney disease, according to a study by researchers at the National Institutes of Health and other institutions. The study appears ...

Diabetes researchers find switch for fatty liver disease

May 17, 2018
Duke researchers have identified a key fork in the road for the way the liver deals with carbohydrates, fats and protein. They say it could be a promising new target for combating the pandemics of fatty liver disease and ...

New study of youth with type 1 diabetes connects 'honeymoon period' with lower LDL cholesterol

May 17, 2018
A new study by UMass Medical School physician-scientist Benjamin U. Nwosu, MD, finds that children with type 1 diabetes who experienced a partial clinical remission, or "honeymoon phase," had significantly lower low-density ...

"Living drug factories" may one day replace injections

May 17, 2018
Patients with diabetes generally rely on constant injections of insulin to control their disease. But MIT spinout Sigilon Therapeutics is developing an implantable, insulin-producing device that may one day make injections ...

Boosting the effects of vitamin D to tackle diabetes

May 10, 2018
More than 27 million people in the United States are living with type 2 diabetes, according to the Centers for Disease Control and Prevention. As the population ages and a growing percentage of people become overweight or ...

Very-low-carb diet shows promise in type 1 diabetes

May 7, 2018
Very-low-carbohydrate diets can improve blood sugar control in type 1 diabetes, with low rates of hypoglycemia and other complications, according to an online patient survey. The researchers, led by Belinda Lennerz, MD, PhD, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.